Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

BIERMER

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Journal of Viral Hepatitis|June 28, 2016
Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV typeB Fülöp, U Mihm, P Rohde, et al.
Gut|September 12, 2024
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989Lung Yi Mak, Christine I Wooddell, Oliver Lenz, et al.
Clinical Pharmacology and Therapeutics|May 15, 2025
Population Pharmacokinetics of siRNA JNJ-73763989 in Healthy Participants and Patients With Chronic Hepatitis BTetsuro Ogawa, Nele Goeyvaerts, Thomas N Kakuda, et al.
Clinical Pharmacology in Drug Development|November 23, 2022
Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult ParticipantsHaiyan Li, Xiaoye Niu, Yu Zhang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 25, 2015
Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null respondersBalazs Fülöp, Michael Biermer, Markus Cornberg, et al.
Journal of Clinical Pharmacology|February 14, 2023
Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic ImpairmentThomas N Kakuda, Atef Halabi, Gernot Klein, et al.
Gut|November 5, 2025
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT studyPatrick T F Kennedy, Scott Fung, Maria Buti, et al.
Journal of Clinical and Translational Hepatology|April 10, 2025
Prevalence of Hepatitis D Virus Antibody Positivity in Chinese Patients with Chronic Hepatitis B Virus InfectionXieer Liang, Qiaoqiao Chen, Hong Tang, et al.
Journal of Gastroenterology|February 18, 2020
JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 studyTetsuo Takehara, Kazuaki Chayama, Masayuki Kurosaki, et al.
Hepatology Communications|February 26, 2025
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis BFlorian van Bömmel, Thierry Verbinnen, Kosh Agarwal, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Journal of Viral Hepatitis|June 28, 2016
Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV typeB Fülöp, U Mihm, P Rohde, et al.
Gut|September 12, 2024
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989Lung Yi Mak, Christine I Wooddell, Oliver Lenz, et al.
Clinical Pharmacology and Therapeutics|May 15, 2025
Population Pharmacokinetics of siRNA JNJ-73763989 in Healthy Participants and Patients With Chronic Hepatitis BTetsuro Ogawa, Nele Goeyvaerts, Thomas N Kakuda, et al.
Clinical Pharmacology in Drug Development|November 23, 2022
Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult ParticipantsHaiyan Li, Xiaoye Niu, Yu Zhang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 25, 2015
Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null respondersBalazs Fülöp, Michael Biermer, Markus Cornberg, et al.
Journal of Clinical Pharmacology|February 14, 2023
Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic ImpairmentThomas N Kakuda, Atef Halabi, Gernot Klein, et al.
Gut|November 5, 2025
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT studyPatrick T F Kennedy, Scott Fung, Maria Buti, et al.
Journal of Clinical and Translational Hepatology|April 10, 2025
Prevalence of Hepatitis D Virus Antibody Positivity in Chinese Patients with Chronic Hepatitis B Virus InfectionXieer Liang, Qiaoqiao Chen, Hong Tang, et al.
Journal of Gastroenterology|February 18, 2020
JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 studyTetsuo Takehara, Kazuaki Chayama, Masayuki Kurosaki, et al.
Hepatology Communications|February 26, 2025
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis BFlorian van Bömmel, Thierry Verbinnen, Kosh Agarwal, et al.
Pageof 5